News from irlab therapeutics ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 10, 2020, 03:25 ET IRLAB's drug candidate pirepemat featured on cover of top-tier journal JPET

IRLAB announced today that the highly ranked scientific journal JPET selected the chemical structure and the in vitro profile of IRLAB's drug...


Aug 03, 2020, 03:28 ET IRLAB's IRL752 is proposed pirepemat as a unique INN by WHO

IRLAB announced today that the World Health Organization (WHO) has proposed the name pirepemat as the International Nonproprietary Name (INN) for the ...


Jul 09, 2020, 03:33 ET IRLAB's Clinical Drug Candidate IRL752 Published in JPET

IRLAB announced today that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of...


Jun 04, 2020, 03:54 ET IRLAB's Phase IIb/III Study in Parkinson's disease to Target Good ON

IRLAB's clinical Phase IIb/III study with the drug candidate mesdopetam (IRL790) in development for the treatment of levodopa induced dyskinesia...


Mar 23, 2020, 09:32 ET IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders

IRLAB announced today that a publication based on the results of the clinical phase IIa study with IRL752 in patients with Parkinson's disease is...


Feb 04, 2020, 02:58 ET IRLAB's IRL790 Receives New Name `mesdopetam'

IRLAB has decided to use the name mesopedam for its drug candidate IRL790 following the recommendation for International Nonproprietary Name (INN) by ...


Dec 12, 2019, 18:36 ET IRLAB Has Carried Out a Directed Issue of SEK 70 Million and Resolves on a Rights Issue of Approximately SEK 145 Million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA,...


Nov 06, 2019, 04:53 ET IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe

IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective...


Sep 23, 2019, 02:45 ET IRLAB Presents at the 2019 International Congress of Parkinson's Disease and Movement Disorders

IRLAB announced today that Prof. Per Svenningsson, on behalf of IRLAB, will be presenting a poster titled "A phase IIa trial studying the safety and...


Aug 28, 2019, 01:16 ET IRLAB to Advance Clinical Development of IRL790 in LIDs Based on In-depth Analysis of Positive Phase IIa Results

IRLAB (Nasdaq First North Premier: IRLAB A) today announced that the in-depth analysis of the data from the recently concluded Phase IIa study of...